NBTX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to negative earnings and equity.
- P/S ratio of 47.36 is unsustainable
- Negative Price/Book ratio
- Forward P/E is prohibitively high
Growth is speculative and not yet reflected in revenue streams.
- Strong analyst backing
- Positive EPS surprise trend
- High burn rate
- Dependence on single-product success
Price performance has decoupled from financial fundamentals.
- Massive 1Y and 3Y returns
- Strong price momentum
- Historical losses
Piotroski score indicates a high probability of continued financial distress.
- Current ratio slightly above 1.0
- Piotroski F-Score of 2/9
- Negative equity
- Deeply negative operating margins
Dividend strength is 0/100.
- No dividend paid
- No capacity for dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NBTX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NBTX
Nanobiotix S.A.
Primary
|
+91.8% | +705.8% | +855.9% | +12.8% | -6.4% | +5.6% |
|
IOVA
Iovance Biotherapeutics, Inc.
Peer
|
-87.4% | -32.7% | +20.9% | +76.2% | -23.6% | +7.9% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
|
IMCR
Immunocore Holdings plc
Peer
|
-3.6% | -38.5% | +20.3% | -4.2% | -4.5% | +0.7% |
|
ANIP
ANI Pharmaceuticals, Inc.
Peer
|
+113.5% | +73.9% | +14.7% | -27.9% | -7.5% | -4.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NBTX
Nanobiotix S.A.
|
BEARISH | $1.54B | - | -% | -73.5% | $31.83 | |
|
IOVA
Iovance Biotherapeutics, Inc.
|
NEUTRAL | $1.52B | - | -55.5% | -148.4% | $3.7 | Compare |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | Compare |
|
IMCR
Immunocore Holdings plc
|
BEARISH | $1.57B | - | -9.6% | -8.9% | $31.05 | Compare |
|
ANIP
ANI Pharmaceuticals, Inc.
|
BEARISH | $1.58B | 21.23 | 16.2% | 8.9% | $70.49 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning NBTX from our newsroom.